Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...

A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 3.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...

Tuesday, Repligen Corporation (NASDAQ:RGEN) reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. The company reported second-quarter adjusted ...

Repligen (NASDAQ:RGEN) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

The latest price target for Repligen (NASDAQ:RGEN) was reported by Benchmark on July 7, 2026. The analyst firm set a price target for $185.00 expecting RGEN to rise to within 12 months (a possible ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...